6 days ago
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data
Relmada Therapeutics (RLMD) stock jumped 31% after Phase 2 bladder cancer trial showed 76% response rate and company secured $160M in funding.
The post Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 7 hours ago
Qualcomm (QCOM) Stock: CFO Dumps Over $330K While Shares Hover Near Annual Lows
- 8 hours ago
5 Undervalued AI Stocks for 2026: Oracle (ORCL), AMD, Micron (MU), TSMC and Dell...
- 9 hours ago
Market Preview: Federal Reserve Meeting, Oil Surge Past $100, and Micron (MU) Ea...
- 10 hours ago
Nvidia (NVDA) vs AMD: The Ultimate AI Stock Showdown for 2025
- 10 hours ago
Ciena (CIEN) Stock Named Top Pick by TD Cowen with $425 Price Target